FIELD: biotechnology.
SUBSTANCE: disclosed are expression vectors containing a nucleic acid molecule or nucleic acid molecules containing one or more nucleotide sequences, expressing a host cell containing these vectors and a method of producing an antibody or an antigen-binding fragment thereof, involving culturing a host cell.
EFFECT: inventions are used to treat bleeding disorders and to reduce blood coagulation time.
7 cl, 33 tbl, 29 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOSING REGIMEN FOR TFPI ANTAGONISTS | 2019 |
|
RU2780590C1 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
